In patients with chronic myeloid leukemia (CML), the neoplastic (BCR ± ABL + ) progenitor cells are characterized by an increased proliferative activity. Whether these cells are also resistant to apoptosis and if so, under what conditions remains controversial. We now show that highly puri®ed populations of very primitive neoplastic progenitor cells obtained directly from CML patients survive and proliferate in vitro for several weeks in the absence of any added growth factors (except insulin). In contrast, puri®ed primary normal progenitors maintained under the same conditions die rapidly. Nevertheless, both primary CML cells and BCR ± ABL + BAF3 cells show the same dose-dependent sensitivity to TNF-a or ceramide-induced apoptosis as their respective normal counterparts. In fact, time course studies demonstrated an even faster onset of apoptosis in ceramide-treated BCR ± ABL + BAF3 cells as compared to normal controls. BCR ± ABL + cells treated with ceramide also showed a rapid and sequential increase in the tyrosine phosphorylation of p210 BCR ± ABL , p46-56 SHC and p120
Cbl . These ®ndings suggest growth factor deprivation and treatment with TNF-a or ceramide trigger dierent initial events both of which can lead to apoptosis in factor-dependent hematopoietic cells. However, in the ®rst case, activation of apoptosis is blocked by the basal activity of p210
Introduction
Chronic myeloid leukemia (CML) is a multistep malignancy which results from the initial acquisition by a pluripotent hematopoietic stem cell of a unique fusion gene (BCR ± ABL) (Fialkow et al., 1981; Groen and Heisterkamp, 1987) . The BCR ± ABL fusion gene produces a hybrid 8.5 kb mRNA and a 210 kDa protein (p210 BCR ± ABL ) with altered properties from the normal 145 kDa ABL gene product. These include an increased tyrosine kinase activity and an exclusively cytoplasmic localization (Konopka and Witte, 1985; Van Etten et al., 1989) . The concordance observed between the presence of the BCR ± ABL gene and the development of CML in humans (Bartram et al., 1983; Wiedemann et al., 1988) , as well as laboratory studies of BCR ± ABL gene transfer to normal cells (Daley et al., 1990; Kelliher et al., 1990) and antisense eects seen in BCR ± ABL + cells (Szczylik et al., 1991) , argue that p210 BCR ± ABL plays a critical role in the pathogenesis of CML. Because the tyrosine kinase function of p210 BCR ± ABL is essential to its transforming ability (Lugo et al., 1990; Cortez et al., 1995) , it has been anticipated that identi®cation of its substrates would facilitate elucidation of the mechanisms by which BCR ± ABL-transformed hematopoietic stem cells initiate CML in humans.
The neoplastic progenitor cells from CML patients show an increased proliferative activity both in vitro and in vivo (Eaves et al., 1986; Eaves and Eaves, 1987; Ponchio et al., 1995) . In spite of this, the self-renewal potential of the more primitive CML cells appears to be decreased (Udomsakdi et al., 1992; Petzer et al., 1997) . The mechanisms that control these responses in normal cells are not yet understood, although certain types of CML progenitors appear to be unresponsive to the inhibitory eects that MIP-1a exerts on the cell cycle progression of primitive normal hematopoietic progenitors (Eaves et al., 1993) whereas the ability of TGF-b to inhibit their proliferation appears to be unaltered (Cashman et al., 1992) . This selective unresponsiveness of primitive CML cells to regulation by MIP-1a (or functionally equivalent chemokines) may thus contribute to the deregulated proliferative activity they exhibit both in vivo and when cocultured with marrow stromal cells. Additional mechanisms are also likely to contribute to the abnormal expansion of BCR ± ABL + cells that occurs in CML patients. In this regard, considerable interest has recently focussed on the observation that BCR ± ABL + hematopoietic cells become factor-independent, in contrast to normal hematopoietic cells which require exogenous growth factor stimulation to sustain their viability (Daley and Baltimore, 1988; Hariharan et al., 1988; Strife et al., 1988; Sirard et al., 1994; Bedi et al., 1994) . This antiapoptotic activity of p210
BCR ± ABL appears to be dependent on the integrity of its kinase function (Carlesso et al., 1994; Kabarowski et al., 1994; McGahon et al., 1994; Cortez et al., 1995) and may also involve elevations in the expression of Bcl-2 (Sanchez-Garcia and Grutz, 1995) and c-myc (Cleveland et al., 1989; Sawyers et al., 1992; Cortez et al., 1995) . However, the response of primary CML cells to other treatments that induce apoptosis in normal cells has remained controversial.
Ceramide is an intracellular lipid signal-transducing intermediate produced by the hydrolysis of membrane sphingolipids in response to a variety of signals, including those activated by the binding of TNF-a and Fas to their respective receptors (Obeid et al., 1993; Hannun and Obeid, 1995; Gulbins et al., 1995) .
The sphingolipid signaling pathway has been implicated in the induction of apoptosis as well as in the regulation of normal cell dierentiation and proliferation (Okazaki et al., 1990; Kim et al., 1991; Wol et al., 1994; Hannun and Obeid, 1995; Jayadev et al., 1995) . Ceramide has also been reported to have at least two eects that appear opposite to those associated with BCR ± ABL expression: i.e., the down-regulation of expression of both c-myc and Bcl-2 (Wol et al., 1994; Chen et al., 1995) . It was, therefore, of interest to compare the responses of BCR ± ABL + and control cells to factor-deprivation, TNF-a and ceramide. The results of such studies showed that both primary CML cells and BCR ± ABL-transformed cell lines can be factor-independent for survival and growth yet remain as sensitive as their normal (BCR ± ABL 7 ) counterparts to the apoptosis-inducing eect of ceramide (or TNFa) with the presence of BCR ± ABL actually causing an accelerated onset of apoptosis in response to these latter two agents. Interestingly, ceramide treatment was also found to induce a rapid, selective and sequential increase in the tyrosine phosphorylation levels of p210 BCR ± ABL , p46-56 SHC and p120
Cbl in BCR ± ABLtransformed cells, suggesting a functional role of these intermediates in accelerating the ceramide-induced apoptotic response.
Results
Ability of primitive CML cells to survive and proliferate in serum-free culture without added growth factors Figure 1 shows the dramatic dierential eect of growth factor deprivation on very primitive normal and CML cells maintained in vitro for up to 3 weeks. To eliminate potential unknown variables that might be introduced with dierent batches of serum, a de®ned serum substitute was used in these experiments. The cultures were initiated with highly puri®ed populations of CD34 + CD71 7 CD45RA 7 cells obtained both from normal donors and from a series of selected CML patients in whom this rare subpopulation of primitive cells had been previously shown to be exclusively BCR ± ABL + /Ph + (Maguer-Satta et al., 1996; Petzer et al., 1996a) . As reported previously (Lansdorp and Dragowska, 1992) , the normal CD34
cells generated large numbers of progeny in vitro when stimulated with a combination of ®ve growth factors which maximise the proliferation of early normal cells (Petzer et al., 1996b ) and a similar result was obtained in cultures of CML cells exposed to these growth factors. When aliquots of the normal cells were cultured under the same conditions but in the absence of the ®ve growth factors, their viability, as expected (Sutherland et al., 1991; Petzer et al., 1996b) , was rapidly lost. In contrast, in cultures initiated with CD34 + CD71 7 CD45RA 7 CML cells, the total cell number expanded rapidly and consistently (*100-fold by 3 weeks), independent of growth factor addition. This included the generation of increased numbers of CFC, although this increase was less than when growth factors were present (10-fold after 3 weeks in the presence of factors vs ®vefold in the absence of factors, Figure 1 ). These results demonstrate for the ®rst time the sustained survival and proliferation of primary CML progenitors that can occur in the absence of any exogenously added hematopoietic growth factors (except insulin which was present in the serum substitute).
Normal sensitivity of CML cells to the apoptosisinducing eect of C2-ceramide
We then compared the ability of C2-ceramide (a cell permeable analogue of ceramide) and TNF-a (which activates the production of ceramide) to induce DNA 
CD45RA
7 cells were isolated from normal bone marrow (NBM, circles) and CML PB (squares) cells by FACS and then incubated in medium containing a de®ned serum substitute (at 10 3 cells/ml) in the presence (solid symbols) or absence (open symbols) of a cocktail of ®ve growth factors (FL, SF, IL-3, IL-6 and G-CSF) for 3, 10 or 20 days. At the end of these times the total number of viable cells (determined by exclusion of trypan blue, left panel) and the number of clonogenic progenitors (determined by plating the incubated cells in standard methylcellulose assays containing growth factors) were measured. Results are expressed as the mean fold-change compared to input values+s.e.m. from results obtained in three independent experiments (with three dierent NBM and CML PB samples)
Ceramide effects on BCR ± ABL + cells V Maguer-Satta et al fragmentation in primary normal and CML cells. Because of the large numbers of cells required to perform these measurements, puri®ed subpopulations of primitive cells could not be used and the eects on aliquots of the light density fraction of each sample were therefore measured. As shown in Table 1 , exposure of both normal and CML cells to either 50 mM C2-ceramide or 100 ng/ml TNF-a reproducibly resulted in a modest but signi®cant (P50.05) increase in the proportion of apoptotic cells after 18 ± 48 h, as assessed by FACS analysis of PI stained cells. Representative plots are shown in Figure 2 . Similar eects were seen for cells exposed to 25 mM C2-ceramide or when the cells were cultured in medium containing the same serum substitute used in the experiments described in Figure 1 (data not shown). To determine whether primary normal and CML cells have similar or dierent sensitivities to the apoptosis-inducing eects of C2-ceramide (or TNFa), an alternative approach based on inhibition of colony formation by primary progenitors cultured in methylcellulose-containing medium was used. As shown in Figure 3 , incorporation of dierent concentrations of C2-ceramide or TNF-a into this assay medium resulted in a similarly modest eect as had been observed in the suspension cultures ( Figure 2 , Table 1 ), but there was no obvious dierence in the sensitivity (dose-response) of normal vs CML progenitors to the inhibitory eect of C2-ceramide or TNF-a on colony formation.
Eects of BCR ± ABL on the viability of C2-ceramide or TNF-a-treated BAF3 cells
Because of the heterogeneity of cell types present in primary normal and CML blood and marrow cell Light density normal or CML bone marrow cells were incubated at 10 6 per ml in medium with 10% FCS at 378C for the times shown and then the proportion of cells containing fragmented nuclear DNA was analysed by¯ow cytometry as described in Materials and methods and illustrated in Figure 3 . NEO ± and BCR ± ABL + BAF3 cells were similarly incubated at 10 5 per ml and analysed (see also Figure 5 ). The results shown are the mean+s.e.m. of values obtained from 3 ± 5 independent experiments with each cell type assessed for the increased numbers of apoptotic cells measured at each time point (+1 ± +48 h) relative to control values (measured in parallel cultures containing neither C2-ceramide nor TNF-a but incubated for the same period of time). Increases that are signi®cantly higher (P50.05) than their respective controls are indicated by an asterisk Figure 2 C2-ceramide and TNF-a-induced DNA fragmentation in NBM and CML PB cells. Light density cells were placed in Iscove's medium supplemented with 10% FCS and varying concentrations of C2-ceramide or TNF-a. After 18 h at 378C, the cells were harvested, washed once in PBS, lysed in a buer containing 20 mg/ml of PI and the DNA content of the lysate analysed bȳ ow cytometry. The number in each histogram represents the percentage of cells with fragmented DNA visualized as the area under the region corresponding to a nuclear chromosomal DNA content of 52 n samples, and the fact that puri®ed subpopulations also cannot be obtained from these in sucient quantities for biochemical studies, we next investigated the eects of C2-ceramide and TNF-a on the murine IL-3-dependent hematopoietic BAF3 cell line (Palacios and Steinmetz, 1985) and derivative lines rendered factorindependent by transfection of a BCR ± ABL plasmid (Daley and Baltimore, 1988) . To minimize the possibility of other mutations contributing to any unique responses seen, early passage G418-resistant BCR ± ABL + and control (NEO + ) cells, selected and cloned as described in the Materials and methods, were used. As expected (Daley and Baltimore, 1988) , the control NEO ± BAF3 cells showed the same dependence on IL-3 for both viability and proliferation as the parental BAF3 cells, whereas all clones of BCR ± ABL + BAF3 cells could sustain their numbers for at least 5 days, although they remained responsive to IL-3 in terms of their ability to show an IL-3 enhancement of their growth. Results of a representative experiment are shown in Figure 4 . The response of these cells to C2-ceramide and TNF-a was then analysed. As shown in Table 1 . Cells were washed twice in PBS, and then incubated in RPMI in the presence of the same serum substitute plus lipids used in the experiments described in Figure 1 and, either no IL-3 (&), or 5 ng/ml (*), or 10 ng/ml (*) of IL-3. The number of viable cells was then evaluated by hemacytometer counts of trypan blue excluding cells. Results are from a representative experiment Ceramide effects on BCR ± ABL + cells V Maguer-Satta et al ABL + BAF3 to be similarly sensitive to the toxic eect of C2-ceramide. In the same experiments, FACS analysis of apoptotic cells after 18 h revealed BCR ± ABL + BAF3 cells to be somewhat more sensitive than the parental or NEO ± BAF3 cells ( Figure 5 , right panel). By 4 days, there were slightly more viable cells in the cultures of BCR ± ABL + BAF3 cells ( Figure 5 , left panel), but these also included a higher frequency of apoptotic cells by comparison to the control cell cultures (data not shown). Similar results were obtained for control (NEO ± BAF3) and BCR ± ABL + BAF3 cells exposed to C2-ceramide (50 mM) or TNF-a (100 ng/ml) in medium containing the same serum substitute used in experiments with primary cells and 5 ng/ml of IL-3 (data not shown).
Interestingly, assessment of the rate at which an increased number of apoptotic cells appeared in cultures containing C2-ceramide (50 mM) or TNF-a (100 ng/ml) showed that in both cases the response of the BAF3 cells was faster (Table 1) . To investigate this further, a more detailed time course study was then performed using Annexin V + staining to monitor an earlier but, nevertheless, irreversible, step in the induction of apoptosis than that detected by PI staining . Preliminary experiments showed that maximum numbers of Annexin V + cells were seen within 2 h of treatment (data not shown). Figure 6 shows the pooled results of three subsequent experiments in which the cells were exposed to 30 mM C2-ceramide (or various other ceramide analogs at the same concentration in protein-free medium) or 100 ng/ ml TNF-a after 1 h prior incubation in the absence of any serum or proteins (to enhance the eects seen in preliminary experiments undertaken with cells incubated in medium containing 10% FCS or the serum substitute). It can be seen that C2-ceramide-treatment caused BCR ± ABL + BAF3 cells to become Annexin V + much more rapidly than parental-BAF3 cells, the former reaching near plateau levels within 15 min, whereas near plateau numbers of Annexin V + parental-BAF3 cells were not seen until after 30 min of exposure to C2-ceramide. A similarly accelerated apoptotic response of BCR ± ABL + BAF3 cells to C6-ceramide was seen. Neither the BCR ± ABL + BAF3 cells nor the control BAF3 cells showed any response to treatment 30 mM dihydro-C2-ceramide or the concentration of ethanol included in all of the ceramide treatment groups, thus establishing the speci®city of the eects obtained with C2-and C6-ceramide. This accelerated eect of 50 mM C2-ceramide treatment on the induction of apoptosis was also seen in two other clones of BCR ± ABL + BAF3 cells (data not shown).
C2-ceramide treatment causes a rapid sequence of tyrosine phosphorylation events in BCR ± ABLtransformed cells
To investigate the molecular mechanism(s) by which ceramide induces an apoptotic response more rapidly in BCR ± ABL-transformed cells, we next examined the eect of C2-ceramide on tyrosine phosphorylation events in normal and BCR ± ABL-transformed cells. In these experiments, primary normal marrow and CML cells, K562 cells (a Ph + /BCR ± ABL + cell line derived from a patient with CML in blast crisis (Lozzio and Lozzio, 1975) ), U937 cells (another human, but Ph 7 /BCR ± ABL 7 myeloid cell line (Sundstrom and Nilsson, 1976) ), as well as NEO ± BAF3 and BCR ± ABL + BAF3 cells were treated with C2-ceramide for dierent times and then Western analyses performed on NP-40 solubilized total cell lysates using antiphosphotyrosine antibodies. As can be seen in Figure  7 , a number of proteins in both K562 and BCR ± 
ABL
+ BAF3 cells, but not in NEO-BAF3 cells, were rapidly phosphorylated on tyrosine residues in response to C2-ceramide, including those with apparent molecular masses of 210, 120 and 46 ± 56 kDa. Similar results were seen with primary CML cells but not with normal marrow or U937 cells (data not shown). To establish the identity of the proteins in BCR ± ABL + cells that were rapidly tyrosine phosphorylated in response to ceramide, NP-40 solubilized total cell lysates from NEO ± BAF3 and BCR ± ABL + BAF3 cells that had been treated with C2-ceramide for 30 min were immunoprecipitated with anti-ABL antibodies (which recognize both ABL and BCR ± ABL, Figure 8a ), anti-Shc antibodies (Figure 8b ) or anti-Cbl antibodies (Figure 8c) . Each of the immunoprecipitates was then analysed by SDS ± PAGE and Western blotting. As can be seen in Figure 8 , these analyses indicated the presence of BCR ± ABL, Cbl and the p46 and p52 isoforms of Shc, respectively, in the 210, 120 and 46 ± 56 kDa bands of tyrosine phosphorylated proteins. These results suggest that the timedependent changes in tyrosine phosphorylation seen speci®cally in BCR ± ABL Time course study of the changes in tyrosine phosphorylation of proteins present in various C2-ceramide-treated BCR ± ABL + and control cells. Cells from the human BCR ± ABL + K562 cell line, the murine BCR ± ABL + BAF3 cell line and NEO ± BAF3 cells were serum-starved for 2 h prior to the addition of 50 mM C2-ceramide at 378C. After being incubated for the period indicated, the cells were harvested, washed and total cell lysates prepared and then separated by SDS ± PAGE prior to Western blotting using an anti-tyrosine phosphorylation antibody 
of data pooled from three independent experiments
Ceramide effects on BCR ± ABL + cells V Maguer-Satta et al phosphorylation of BCR ± ABL (which was maximal within 10 min) followed by the tyrosine phosphorylation of Cbl and Shc (which were still increasing after 30 ± 60 min of exposure to C2-ceramide). Of note, the protein-speci®c immunoprecipitation studies indicated that BCR ± ABL was present in the anti-Cbl immunoprecipitates (Figure 8c) , consistent with the possibility that ceramide activates BCR ± ABL which then phosphorylates tyrosine residues on Cbl. The speci®c immunoprecipitation studies also revealed that short term exposure of BCR ± ABL + BAF3 cells, but not NEO ± BAF3 cells to C2-ceramide induced an association of Shc with a tyrosine phosphorylated form of SHIP (Figure 8b ), an SH2-containing 5-phosphatase Lioubin et al., 1996) recently implicated in mediating apoptosis and negative signaling (Liu et al., 1997; Lioubin et al., 1996; Chacko et al., 1996; Ono et al., 1996) . 
Discussion
The present studies were intially designed to examine the eects of p210 BCR ± ABL on the sensitivity of primitive hematopoietic cells to the induction of apoptosis by two dierent treatments: growth factor deprivation and exposure to C2-ceramide (or TNF-a). Previous studies have reported that, in the absence of exogenous hematopoietic growth factors, CD34 + cells, including CFU-GM, decline more rapidly in serum-containing cultures of marrow cells from normal individuals than from patients with CML (Bedi et al., 1994; Strife et al., 1988) although others have not con®rmed this (Amos et al., 1995; Albrecht et al., 1996; Nishii et al., 1996) . In this study, we revisited this question focusing for the ®rst time on a minor subpopulation of CD34 + cells that contains the most primitive hematopoietic cell types and thus represents a more highly enriched suspension of these cells regardless of their normal (Lansdorp and Dragowska, 1992; Sauvageau et al., 1994; Hogge et al., 1996) or CML (Ph + /BCR ± ABL) origin (Petzer et al., 1996a) . In addition, we were able to examine the response of these cells to growth factor deprivation in a de®ned medium to which the only added proteins were BSA, transferrin and insulin, thus excluding potential eects of unknown factors present in serum. The results of our experiments show that very primitive CML cells are abnormal in their ability not only to survive under these conditions, but also to proliferate and dierentiate. As a result, ampli®ed numbers of leukemic progeny, including those detectable as colony-forming progenitors in semi-solid media, can be selectively generated when growth factor levels are limiting (Figure 1) . The fact that the very CML cell types shown here to exhibit growth factor-independent survival and proliferation have also been shown to express BCR ± ABL mRNA (Maguer-Satta et al., 1996) supports the view that p210 BCR ± ABL is responsible for these abnormal growth properties as well as the increased cycling activity exhibited by Ph + /BCR ± ABL + progenitors in patient marrow and blood samples Eaves, 1987 and .
It is now widely appreciated that an apoptotic response can be triggered by a variety of perturbations of cellular activity. Of particular interest to this discussion are those caused by agents such as ionizing radiation and various chemotherapeutic drugs commonly used for treating CML patients, particularly where ablation of the leukemic clone is sought. Examination of the response of primary CML cells or BCR ± ABL + cell lines to such agents has yielded controversial results, some suggesting a sensitizing or no eect of p210 BCR ± ABL and some suggesting a protective (anti-apoptotic) eect (Santucci et al., 1993; McGahon et al., 1994; Amos et al., 1995; Bedi et al., 1995; Albrecht et al., 1996; Nishii et al., 1996) . In view of the role of ceramide as a common mediator of drug, radiation and TNF-a-induced apoptosis (Obeid et al., 1993; Jarvis et al., 1994; Kolesnick and Golde, 1994; Hannun and Obeid, 1995; Bose et al., 1995; Muller et al., 1995; Adam-Klages et al., 1996) , we undertook experiments to examine whether p210 BCR ± ABL might aect the induction of apoptosis by treatments that involve raising intracellular levels of ceramide. Our results with both primary CML cells and BCR ± ABL-transformants of an originally factordependent cell line show unequivocally that p210 BCR ± ABL does not decrease the sensitivity (in a dose-dependent fashion) of hematopoietic cells to the apoptosis-inducing eects of either C2-ceramide or TNF-a (Figures 3 and 5) . In fact, time course studies indicated that the initiation of apoptosis by these agents can be faster in cells expressing p210 BCR ± ABL (Table 1 and Figure 6 ).
Taken together, these results suggest that the sequence of events leading to apoptosis of hematopoietic cells following growth factor (IL-3) withdrawal can be blocked by the action of p210 BCR ± ABL whereas those initiated by treatment with TNF-a or C2-ceramide may be accelerated. This eect of p210 BCR ± ABL on C2-ceramide-induced apoptosis was most clearly demonstrated here using surface Annexin V labeling. This detects the transfer of phosphatidylserine (to which Annexin V speci®cally binds) from the inner layer of the plasma membrane of viable cells to the outer layer, an early but irreversible step in cells undergoing apoptosis . For both the parental and NEO-containing IL-3-dependent BAF3 cells, exteriorization of phosphatidylserine required more prolonged exposure to C2-ceramide than was the case for their BCR ± ABL + counterparts. Speci®city of the C2-ceramide eects seen on both BCR ± ABL + and control BAF3 cells was established from the demonstration of their anticipated responses to active (i.e. C6-ceramide) and inactive (dihydro-C2-ceramide) analogs of C2-ceramide.
Given the well known tyrosine kinase function of p210 BCR ± ABL and its ability to be regulated (Lugo et al., 1990) , we then sought to explore its potential involvement in ceramide-induced apoptosis by comparing the type and time course of tyrosine phosphorylation events seen in C2-ceramide-treated BCR ± ABL + and BCR ± ABL 7 cells. Such studies showed an early and selectively increased tyrosine phosphorylation of several proteins in BCR ± ABL + cells, including p210 BCR ± ABL , itself, which was the ®rst to be aected (Figure 7) . The mechanism by which ceramide (and TNF-a) might induce a rapid increase in tyrosine phosphorylated BCR ± ABL was not further investigated here. However, the recently described ceramide-activated protein kinase (CAPK) (Mathias et al., 1991) which is a membrane-associated serine/threonine kinase identical to the kinase suppressor of Ras (KSR) (Zhang et al., 1997) , or other mechanisms resulting from the intracellular conversion of ceramide to sphingosine (Ohta et al., 1994) are possibilities for future studies. After BCR ± ABL, two other proteins, p120
CBL and p46-56 SHC , also showed increased levels of tyrosine phosphorylation in the C2-ceramide-treated BCR ± ABL + cells (Figures 7  and 8 ). Both p120 CBL and p46-56 SHC have been previously demonstrated to possess increased basal levels of tyrosine phosphorylation in BCR ± ABLtransformed cells (Andoniou et al., 1994; Puil et al., 1994; Tauchi et al., 1994; de Jong et al., 1995) and are known to be substrates of the BCR ± ABL-encoded tyrosine kinase (Andoniou et al., 1994; Matsuguchi et al., 1994; Puil et al., 1994; Tauchi et al., 1994) . These events could be explained by a model of ceramide action involving the p210 BCR ± ABL -dependent activation of two initially dierent but converging pathways Ceramide effects on BCR ± ABL + cells V Maguer-Satta et al culminating in apoptosis: the Ras pathway through p46-56 SHC (Goga et al., 1995) and the PI3-kinase pathway through p120 CBL (Kim et al., 1995; Skorski et al., 1995; Sattler et al., 1996) . Interestingly, TNF-a has been reported to activate the Ras pathway through Shc to induce cell death (Trent II et al., 1996) and activation of Cbl and PI3-kinase are thought to play a role in the induction of apoptosis in immature lymphoid cells (Kitanaka et al., 1996) .
Another protein showing increased tyrosine phosphorylation in BCR ± ABL + cells was p145
SHIP
, an SH2-containing inositol phosphatase that might compete with Grb2 for Shc (Figure 8 ). This 5-phosphatase selectively dephosphorylates inositol-1,3,4,5-tetraphosphate (IP 4 ) and phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-P 3 ) Liu et al., 1997) , two inositol polyphosphates recently implicated in growth factor-mediated signaling (Toker et al., 1994; Franke et al., 1995; Rameh et al., 1995; Cullen et al., 1995) . In addition, we (Liu et al., 1997; Chacko et al., 1996) and others (Lioubin et al., 1996; Ono et al., 1996) have obtained evidence that SHIP has an antiproliferative activity and is involved in the induction of apoptosis in hematopoietic cells. Moreover, its SH2 (Shc-binding) domain appears to be essential for its apoptotic eect (Liu et al., 1997) .
Our observations described here for ceramide appear similar to those very recently reported by Selleri et al. (1997) who noted a more marked induction of apoptosis in CML cells following activation of the Fas receptor. Of interest, previous studies have indicated that Fas-induced apoptosis is mediated by ceramide activation of Ras (Gulbins et al., 1995) . Taken together, these results suggest that p210 BCR ± ABL can have opposite eects on the induction of apoptosis in hematopoietic cells; a protective eect on cells that would otherwise be compromised by withdrawal of growth factors, and an apoptosis-accelerating eect of ceramide on BCR ± ABL + as compared to normal cells, independent of the presence of growth factors. Future studies will be necessary to identify the mechanism(s) by which ceramide activates p210 BCR ± ABL and the downstream pathways responsible for accelerating the onset of apoptosis.
Materials and methods

Cell lines and reagents
U937 cells (Sundstrom and Nilsson, 1976) and K562 cells (Lozzio and Lozzio, 1975) were obtained from the American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 with 10% fetal calf serum (FCS) (StemCell Technologies, Vancouver, BC). BAF3 cells (Palacios and Steinmetz, 1985) were maintained in RPMI 1640 with 10% FCS and 5 ng/ml of highly puri®ed recombinant murine IL-3 (expressed in COS cells). C2-ceramide, dihydro-C2-ceramide and C6-ceramide (all from Sigma Chemicals Co., St. Louis, MO) were prepared as 10 mM stock solutions in 100% ethanol and then diluted as required. Thus, the maximum concentration of ethanol present in any culture was 0.5% (v/v), which in preliminary experiments was shown to have no eect on any of the parameters studied. (See, for example Figure  6 ). TNF-a was purchased from R&D System, Inc. (Minneapolis, MN) .
Primary cells
Heparinized PB and BM aspirate cells from Ph + /BCR ± ABL + CML patients in chronic phase were obtained with informed consent and were leftovers of samples taken for routine diagnostic or follow-up procedures. Samples of normal BM aspirate cells from donors of marrow for allogeneic transplantation were also obtained with informed consent or were from cadaveric donors. Heparinized normal PB cells were obtained from laboratory volunteers. In each case the light density (51.077 g/ml) cell fraction was isolated by centrifugation on Ficoll-Hypaque (Pharmacia, Piscataway, NJ) and then used directly, sorted or cryopreserved in 20% DMSO plus 80% FCS as required. Puri®ed CD34 + CD71 7 CD45RA 7 cells were isolated as previously described (Maguer-Satta et al., 1996; Petzer et al., 1996a) . Brie¯y, cells were ®rst incubated simultaneously with anti-CD34 (8G12-Cy5), anti-CD71 (OKT9-¯uorescein isothiocyanate) and anti-CD45RA (8d2-R-phycoerythrin) at 10, 1 and 2.5 mg/ml for 30 min at 48C, followed by a ®rst wash in Hanks HEPES-buered salt solution with 2% FCS and 0.1% sodium azide (HFN) and a second wash in HFN plus 2 mg/ ml propidium iodide (PI, Sigma) prior to resuspension in HF (no azide). Cells with medium-high forward light scattering and low side scattering characteristics and a CD34 + CD71 7 CD45RA 7 phenotype were then sorted using a FACStar Plus 1 (Becton Dickinson & Co., San Jose, CA) equipped with a 5-W argon laser and a helium-neon laser. Positive (or negative) staining was de®ned as the intensity of¯uorescence that exceeded (or was less than) 99% of that obtained using (irrelevant) isotype-matched control antibodies labeled with the same¯uorochromes.
Serum-free liquid cultures of primary cells
Sorted cells were suspended at 1000 cells/ml in Iscove's medium supplemented with 10 74 M 2-mercaptoethanol (2-ME) and a serum substitute consisting of 20 ng/ml of BSA, 10 mg/ml of human insulin and 200 mg/ml of human transferrin (BIT, StemCell) plus 40 mg/ml low density lipoproteins (Sigma) and, as indicated, the following recombinant human cytokines: 100 ng/ml¯t3-ligand (FL, Immunex Corp, Seattle, WA), 100 ng/ml Steel factor (SF, Amgen Co., Thousand Oaks, CA), 20 ng/ml IL-3 (Sandoz International, Basel, Switzerland), 20 ng/ml G-CSF (Amgen), 20 ng/ml IL-6 (Cangene, Mississauga, ON) and 5 ng/ml NGF-b (R&D). The cells were then incubated unperturbed for 3, 10 or 20 days at 378C in a humidi®ed atmosphere of 5% CO 2 in air and then harvested.
Progenitor assays Cells to be tested were washed and resuspended in Iscove's medium and then appropriate aliquots suspended in Iscove's methylcellulose (MethoCult H4330, StemCell) containing 30% FCS, 1% BSA and 3 U/ml of human erythropoietin (StemCell) and 50 ng/ml of SF (Amgen, Thousand Oaks, CA) and 20 ng/ml each of IL-6 (Cangene, Mississauga, ON), GM-CSF (Sandoz International, Basel, Switzerland), G-CSF (Amgen) and IL-3 (Sandoz) and plated in 35 mm petri dishes. Erythroid, granulocytemacrophage, and mixed-lineage colonies were enumerated in situ after 16 days of incubation at 378C using standard scoring criteria. CFC (colony-forming cell) counts refer to the sum of all of the progenitors measured by scoring these dierent kinds of colonies.
Electroporation of BAF3 cells
BCR ± ABL (and control neo-expressing) BAF3 cells were generated by electroporation of parental BAF3 cells with a Ceramide effects on BCR ± ABL + cells V Maguer-Satta et al MSCV ± BCR ± ABL generated from a MSCV-vector originally obtained from R Hawley (Hawley et al., 1994) . The BCR ± ABL cDNA (Daley and Baltimore, 1988) encoding p210 BCR ± ABL was provided by J Grin (Dana Farber Cancer Institute, Boston, MA) and was then used with neo to generate the MSCV ± BCR ± ABL ± NEO and control MSCV ± NEO vectors by A Turhan (Institute Gustav-Roussy, Paris, France) from whom these vectors were obtained. To electroporate the BAF3 cells, 3610 7 cells were washed once in cold PBS, resuspended in 800 ml of serum-and IL-3-free medium and then incubated for 5 min on ice with 10 mg of MSCV ± NEO or MSCVp210 BCR ± ABL cDNA plasmids linearized with the NdeI enzyme. Cells were then electroporated (250 V, 960 mF) using a Bio-Rad Gene Pulser. Following electroporation, cells were incubated for the ®rst 24 h at 378C in RPMI 1640 plus 10% FCS without G418 (Gibco-BRL, Burlington, ON) which was then added at 2 mg/ml and the cells cloned by growth at limiting cell numbers per culture. G418-resistant clones were thus identi®ed and several clones isolated and expanded for subsequent analysis. All transfected cells were used within an estimated 35 ± 45 cell generations since transfection (assuming a cell generation time of *18 h).
Viability and MTT proliferation assays (Mosmann, 1983) Cells (100 ml of 10 5 cells/ml) were placed in the wells of 96 well¯at bottom plates in medium plus 10% FCS (or BIT plus low density lipids) and 10 74 M 2-ME in the presence or absence of the test chemical as indicated. For each culture condition, samples were set up in triplicate. Cells were then incubated at 378C, in 5% CO 2 in air for 4 days. An aliquot was removed for assessing the number of viable cells present (by trypan blue exclusion) and then 20 ml of a 5 mg/ml solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well and the plates incubated for another 4 h. The reaction was then stopped by adding 100 ml of 0.04 M HC1 in isopropanol to each well. The optical density was then measured using an ELISA plate reader with 630 nm as the reference wavelength and 570 nm as the test wavelength.
Flow cytometric analysis of DNA fragmentation
After treatment, cells were washed once in PBS and the cell pellet then resuspended at 10 6 cells/ml in lysis buer (0.1% sodium citrate, 0.1% Triton X-100, pH=8) containing 20 mg/ml of PI. The samples were then analysed by¯ow cytometry using a FACScan (Becton Dickinson) as previously described (Nicoletti et al., 1991) .
Annexin V-FITC binding assay
Brie¯y, cells were washed in HEPES buer (10 mM HEPES-NaOH, pH=7.4, with 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 ) and then assayed for their ability to bind Annexin V to the extracellular surface following their incubation with 0.1 mg/ml FITC-conjugated Annexin V (Bio-Whittaker, LaJolla, CA) in HEPES buer for 5 min followed by¯ow cytometric analysis as described .
Immunoprecipitation and Western blotting
The various types of exponentially growing BAF3 cells were ®rst incubated in RPMI 1640 in the absence of serum for 2 h at 378C and then washed prior to being treated with various concentrations of C2-ceramide or 100 ng/ml TNF-a. Other cells were simply washed and resuspended in C2-ceramide containing medium without prior incubation in serum-free medium. Cell lysates were prepared using phosphorylation solubilization buer (PSB, 50 mM HEPES buer, pH=7.4, 100 mM NaF, 10 mM NaPPi, 2 mM Na 3 VO 4 , 4 mM EDTA) containing 0.5% NP-40 (protein-grade from Calbiochem, San Diego, CA) and immunoprecipitations and Western analyses were performed using 20610 6 cells/sample as described previously . The anti-phosphotyrosine monoclonal antibody, 4G10, was purchased from UBI (Lake Placid, NY). Anity-puri®ed polyclonal antibodies to Shc (for immunoprecipitation) and monoclonal antibodies to Shc (for Western blotting) were obtained from Transduction Laboratories (Mississauga, ON). The anti-Abl antibody was obtained from Pharmingen (San Diego, CA) and the anti-Cbl antibody from Santa Cruz Biotechnologies, Inc (Santa Cruz, CA). Antiserum to SHIP was generated by immunizing rabbits with a glutathione S-transferase (GST)-SHIP fusion protein containing the SH2 domain of murine SHIP. Horseradish peroxidase-conjugated second antibodies were purchased from Jackson Immunoresearch (West Grove, PA) and the enhanced chemiluminescence Western blotting reagents were from Pierce (Rockford, IL). The protein concentrations of all lysates were measured prior to loading onto the gels to ensure that equal amounts were loaded into all lanes.
